PER.C6® Technology Advantages
-
Human-like glycosylation
-
Rapid development
-
Regulatory acceptance (BMF)
-
High yields
DSM Biologics has co-exclusive rights with Dutch biotech company
Crucell N.V. to license the high-producing PER.C6® human cell line as a
production platform for recombinant proteins and monoclonal antibodies.
The combination of the PER.C6® human cell line and DSM’s manufacturing
services provides companies with biologic manufacturing solutions help you to
reduce cost, risk and time to market.
High Yields
-
12 grams per liter in fed-batch with standard lgG
-
27 grams per liter in XD® with standard lgG
